» Articles » PMID: 21088048

Ron Receptor Deficient Alveolar Myeloid Cells Exacerbate LPS-induced Acute Lung Injury in the Murine Lung

Overview
Journal Innate Immun
Publisher Sage Publications
Date 2010 Nov 20
PMID 21088048
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have shown that the Ron receptor tyrosine kinase is an important regulator of the acute lung inflammatory response induced by intranasal administration of bacterial LPS. Compared to wild-type mice, complete loss of the Ron receptor in all cell types in vivo was associated with increased lung damage as determined by histological analyses and several markers of lung injury including increases in pro-inflammatory cytokines such as TNF-α. Tumor-necrosis factor-α is a multifunctional cytokine secreted by macrophages, which plays a major role in inflammation and is a central mediator of several disease states including rheumatoid arthritis and sepsis. Based on increased TNF-α production observed in the Ron-deficient mice, we hypothesized that Ron receptor function in the inflammatory cell compartment is essential for the regulating lung injury in vivo. To test this hypothesis, we generated myeloid lineage-specific Ron-deficient mice. In this study, we report that loss of Ron signaling selectively in myeloid cells results in increased lung injury following intranasal administration of LPS as measured by increases in TNF-α production, ensuing neutrophil accumulation and increased lung histopathology. These findings corroborate the role of Ron receptor tyrosine kinase as a negative regulator of inflammation and further demonstrate the in vivo significance of Ron signaling selectively in myeloid cells as a major regulator of this response in vivo. These data authenticate Ron as a potential target in innate immunity and TNF-α-mediated pathologies.

Citing Articles

RON () and HGFL () Co-Overexpression Supports Breast Tumorigenesis through Autocrine and Paracrine Cellular Crosstalk.

Hunt B, Jones A, Lester C, Davis J, Benight N, Waltz S Cancers (Basel). 2022; 14(10).

PMID: 35626096 PMC: 9140067. DOI: 10.3390/cancers14102493.


Macrophage-mediated RON signaling supports breast cancer growth and progression through modulation of IL-35.

Ruiz-Torres S, Bourn J, Benight N, Hunt B, Lester C, Waltz S Oncogene. 2021; 41(3):321-333.

PMID: 34743208 PMC: 8758553. DOI: 10.1038/s41388-021-02091-y.


Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4+ T Cells That Subvert Immunosuppression.

Lai S, Gundlapalli H, Ekiz H, Jiang A, Fernandez E, Welm A Cancer Discov. 2021; 11(12):3178-3197.

PMID: 34330779 PMC: 8800951. DOI: 10.1158/2159-8290.CD-20-1172.


MSP-RON Pathway: Potential Regulator of Inflammation and Innate Immunity.

Huang L, Fang X, Shi D, Yao S, Wu W, Fang Q Front Immunol. 2020; 11:569082.

PMID: 33117355 PMC: 7577085. DOI: 10.3389/fimmu.2020.569082.


Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer.

Brown N, Sullivan C, Waltz S EMS Cancer Sci J. 2019; 1(1).

PMID: 30775725 PMC: 6377156.


References
1.
Matute-Bello G, Frevert C, Martin T . Animal models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2008; 295(3):L379-99. PMC: 2536793. DOI: 10.1152/ajplung.00010.2008. View

2.
Warren J, Kunkel S, Cunningham T, Johnson K, Ward P . Macrophage-derived cytokines amplify immune complex-triggered O2-. responses by rat alveolar macrophages. Am J Pathol. 1988; 130(3):489-95. PMC: 1880672. View

3.
Quantin B, Schuhbaur B, Gesnel M, Dolle P, Breathnach R . Restricted expression of the ron gene encoding the macrophage stimulating protein receptor during mouse development. Dev Dyn. 1995; 204(4):383-90. DOI: 10.1002/aja.1002040405. View

4.
Aderem A, Ulevitch R . Toll-like receptors in the induction of the innate immune response. Nature. 2000; 406(6797):782-7. DOI: 10.1038/35021228. View

5.
Shanley T, Warner R, Ward P . The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol Med Today. 1995; 1(1):40-5. DOI: 10.1016/1357-4310(95)80019-0. View